# DuoBody

Type: Technology

Source: GetYourBrief — https://getyourbrief.com/entity/duobody
Canonical HTML page: https://getyourbrief.com/entity/duobody

## Timeline

- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.

## Recent coverage (2 stories, network-wide)

### Epcoritamab Trial Misses Survival Goal—What It Means for DLBCL Patients
2026-08-01 11:31:34 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
Full story: https://gethealthbrief.com/story/epcoritamab-survival-miss-dlbcl-patient-care

### Epcoritamab Phase 3 OS Miss Clouds $300M Revenue Stream for AbbVie and Genmab
2026-08-01 11:31:26 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Full story: https://getbiobrief.com/story/epcoritamab-phase3-os-miss-revenue-risk

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.